

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Duckworth W, Abaira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009;360:129-39. DOI: [10.1056/NEJMoa0808431](https://doi.org/10.1056/NEJMoa0808431).

Supplementary Appendix 1

Time to Primary Event

Primary Event	Treatment	# of Events	6 Year Event Rate	p-value (Log rank)	Hazard Ratio	Lower CL	Upper CL
First Primary Event	Standard	264	0.66	0.14	0.88	0.74	1.05
	Intensive	235	0.70				
MI	Standard	78	0.90	0.24	0.82	0.59	1.14
	Intensive	64	0.91				
CHF	Standard	82	0.89	0.57	0.91	0.67	1.25
	Intensive	76	0.90				
Stroke	Standard	36	0.95	0.32	0.78	0.48	1.28
	Intensive	28	0.96				
Coronary Revascularization	Standard	127	0.83	0.19	0.84	0.65	1.09
	Intensive	107	0.86				
Peripheral Revascularization	Standard	23	0.97	0.66	0.87	0.48	1.59
	Intensive	20	0.97				
Cerebro-revascularization	Standard	15	0.98	0.86	0.94	0.45	1.94
	Intensive	14	0.98				
Amputation	Standard	17	0.98	0.26	0.65	0.31	1.39
	Intensive	11	0.98				
Inoperable CAD	Standard	8	0.98	0.35	1.52	0.62	3.72
	Intensive	12	0.98				
CV Death	Standard	29	0.96	0.26	1.32	0.81	2.14
	Intensive	38	0.95				

Results of analysis of composite primary endpoint and each component of the composite.

Supplementary Appendix 2

Time to Secondary Cardiovascular Events and Total Mortality

Secondary Event	Treatment	# of Events	6 Year Event Rate	p-value (Log rank)	Hazard Ratio	Lower CL	Upper CL
Angina	Standard	139	0.82	0.11	1.20	0.96	1.51
	Intensive	163	0.79				
CLI*	Standard	19	0.97	0.51	0.80	0.40	1.56
	Intensive	15	0.98				
IC**	Standard	17	0.98	0.49	0.78	0.38	1.60
	Intensive	13	0.98				
TIA***	Standard	13	0.98	0.28	1.48	0.73	2.99
	Intensive	19	0.97				
All Cause Mortality	Standard	95	0.88	0.62	1.07	0.81	1.42
	Intensive	102	0.87				

Abbreviations: * CLI= critical limb ischemia, ** IC=intermittent Claudication,
***TIA= transient ischemic attacks

Results of Secondary Macrovascular Events with Treatment

Supplementary Appendix 3

Cause of Cardiovascular Death

	Treatment				Total	
	Standard		Intensive		Total	
	N	%	N	%	N	%
Myocardial infarction	12	1.3	13	1.5	25	1.4
Congestive heart failure	9	1.0	8	0.9	17	0.9
Coronary Revascularization	0	0	1	0.1	1	0.1
Stroke	4	0.4	6	0.7	10	0.6
Cerebrovascularization	1	0.1	0	0	1	0.1
Complications of Occlusions	1	0.1	0	0	1	0.1
Peripheral Revascularization	1	0.1	1	0.1	2	0.1
Sudden Death (p=0.07)	4	0.4	11	1.2	15	0.8
Pulmonary Embolism	1	0.1	0	0	1	0.1
Total Cardiovascular death (p=0.29)	33	3.7	40	4.5	73	4.1

Total Cardiovascular Deaths and Individual Causes. All results are non-significant.

Supplementary Appendix 4A

Cause of Death: Neoplasm (Non-cardiovascular)

	Treatment				Total	
	Standard		Intensive			
	N	%	N	%	N	%
Neoplasm	2	0.2	3	0.3	5	0.3
Lung cancer	7	0.8	6	0.7	13	0.7
Liver cancer	2	0.2	1	0.1	3	0.2
Renal cancer	1	0.1	3	0.3	4	0.2
Colon cancer	2	0.2	4	0.4	6	0.3
Bile duct cancer	0	0	1	0.1	1	0.1
Prostate cancer	0	0	1	0.1	1	0.1
Pancreatic cancer	1	0.1	4	0.4	5	0.3
Lymphatic cancer	2	0.2	0	0	2	0.1
Other	4	0.4	1	0.1	5	0.3
Total Neoplasm	21	2.3	24	2.7	45	2.5

All results are non-significant

Supplementary Appendix 4B

Other Causes of Death (Non-cardiovascular)

	Treatment				Total	
	Standard		Intensive			
	N	%	N	%	N	%
Infection	3	0.3	3	0.3	6	0.3
Unknown	14	1.6	6	0.7	20	1.1
Suicide	3	0.3	3	0.3	6	0.3
Pancreatitis and complications	1	0.1	2	0.2	3	0.2
Acute morphine and temazepam intoxication	1	0.1	1	0.1	2	0.1
Renal failure	3	0.3	2	0.2	5	0.3
Respiratory failure	5	0.6	7	0.8	12	0.7
Other	11	1.2	14	1.6	25	1.4
Total non-CV, non-neoplastic deaths	41	4.6	38	4.3	79	4.4

Non cardiovascular and non-neoplastic causes of death. All non-significant.

Supplementary Appendix 5

Reporting of Confirmed SAE at least once during follow-up*

Number of patients reporting Serious Adverse Events	Standard		Intensive		P-value
	N	%	N	%	
ALL	899	100.0	892	100.0	
never reported	741	82.4	677	75.9	0.001
dyspnea SAE	65	7.2	98	11.0	0.006
hypoglycemia SAE	28	3.1	76	8.5	0.000
edema SAE	46	5.1	58	6.5	0.210
altered consciousness (not associated with hypoglycemia) SAE	27	3.0	28	3.1	0.868
weakness/numbness of limb(s) SAE	17	1.9	25	2.8	0.202
nausea SAE	18	2.0	22	2.5	0.506
vomiting SAE	15	1.7	20	2.2	0.381
upper respiratory infection SAE	13	1.4	19	2.1	0.275
vertigo SAE	11	1.2	14	1.6	0.533
diarrhea SAE	6	0.7	13	1.5	0.103
blurred or double vision SAE	7	0.8	13	1.5	0.172
hyperglycemia SAE	15	1.7	11	1.2	0.441
newly appearing or worsening headaches SAE	9	1.0	11	1.2	0.640
neuropathic ulcer SAE	9	1.0	6	0.7	0.446
dysphasia SAE	5	0.6	5	0.6	1.000
ataxia SAE	8	0.9	4	0.4	0.252
dysarthria SAE	4	0.4	4	0.4	1.000
pruritus SAE	0	0	2	0.2	0.248
skin ulcers (other than extremity ulcers) SAE	5	0.6	2	0.2	0.452
erectile/sexual dysfunction SAE	1	0.1	1	0.1	1.000
jaundice SAE	2	0.2	1	0.1	1.000
rash SAE	1	0.1	1	0.1	1.000
nystagmus SAE	1	0.1	0	0	1.000

*SAE: Life threatening, death, hospitalization, disability or incapacity, cancer or other important event requiring medical intervention/treatment.